Analyst Ratings for Pharmacyclics (PCYC) [Buys]
PCYC Rating Summary
PCYC Price Target Summary
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$69.77 (-18.5%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/13/2013 | RBC Capital | Upgrade | Outperform (Sector Perform) |
100.00 (70.00) |
79.00 | 85.61 | 8.37% | Details |
| 2/8/2013 | JMP Securities | New Coverage | Market Outperform (N/A) |
104.00 (N/A) |
69.28 | 85.61 | 23.57% | Details |
| 1/15/2013 | Credit Suisse | New Coverage | Outperform (N/A) |
79.00 (N/A) |
65.15 | 85.61 | 31.4% | Details |
| 11/1/2012 | Piper Jaffray | New Coverage | Overweight (N/A) |
83.00 (N/A) |
61.07 | 85.61 | 40.18% | Details |
| 6/15/2012 | SunTrust Robinson Humphrey | New Coverage | Buy (N/A) |
48.00 (N/A) |
40.52 | 85.61 | 111.28% | Details |
| 6/7/2012 | Brean Capital | New Coverage | Buy (N/A) |
80.00 (N/A) |
34.77 | 85.61 | 146.22% | Details |
| 12/7/2011 | Rodman & Renshaw | New Coverage | Market Outperform (N/A) |
20.00 (N/A) |
15.14 | 85.61 | 465.46% | Details |
| 1/3/2011 | Chardan Capital | New Coverage | Buy (N/A) |
N/A (N/A) |
6.08 | 85.61 | 1308.06% | Details |
